Search research articles
Contact Us
Filters
Showing results (1-10 of 10) with videos related to
Page
of 1
Sort By:
Science (New York, N.Y.)
|
July 16, 1993
Quarks bottom to top
H E Haber
Cardiovascular Drugs and Therapy
|
August 10, 1999
Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. TREND Investigators. Trial on Reversing Endothelial Dysfunction
J D Schlaifer, G B Mancini, B J O'Neill, et al.
Cardiovascular Drugs and Therapy
|
April 1, 1997
Activity of Procanbid, procainamide twice-daily formulation, to suppress ventricular premature depolarizations. The Study Group Investigators
N Z Kerin, W L Meengs, G C Timmis, et al.
Clinical Cardiology
|
May 22, 1998
Influence of smoking status on progression of endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction
C J Pepine, J D Schlaifer, G B Mancini, et al.
The American Journal of Cardiology
|
January 7, 1998
Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction
J D Schlaifer, T J Wargovich, B O'Neill, et al.
The American Journal of Cardiology
|
August 1, 1997
Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals
M H Davidson, J W Nawrocki, S R Weiss, et al.
The American Journal of Cardiology
|
November 1, 1996
Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) Trial
R S Lees, B Pitt, R C Chan, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
May 1, 1995
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
J W Nawrocki, S R Weiss, M H Davidson, et al.
Cardiovascular Drugs and Therapy
|
April 8, 2000
Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators
M Oosterga, A A Voors, H Buikema, et al.
Circulation
|
August 1, 1996
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study
G B Mancini, G C Henry, C Macaya, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 10) with videos related to
Sort By:
Page
of 1
Science (New York, N.Y.)
|
July 16, 1993
Quarks bottom to top
H E Haber
Cardiovascular Drugs and Therapy
|
August 10, 1999
Influence of smoking status on angiotensin-converting enzyme inhibition-related improvement in coronary endothelial function. TREND Investigators. Trial on Reversing Endothelial Dysfunction
J D Schlaifer, G B Mancini, B J O'Neill, et al.
Cardiovascular Drugs and Therapy
|
April 1, 1997
Activity of Procanbid, procainamide twice-daily formulation, to suppress ventricular premature depolarizations. The Study Group Investigators
N Z Kerin, W L Meengs, G C Timmis, et al.
Clinical Cardiology
|
May 22, 1998
Influence of smoking status on progression of endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction
C J Pepine, J D Schlaifer, G B Mancini, et al.
The American Journal of Cardiology
|
January 7, 1998
Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. TREND Investigators. Trial on Reversing Endothelial Dysfunction
J D Schlaifer, T J Wargovich, B O'Neill, et al.
The American Journal of Cardiology
|
August 1, 1997
Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Program treatment goals
M H Davidson, J W Nawrocki, S R Weiss, et al.
The American Journal of Cardiology
|
November 1, 1996
Baseline clinical and angiographic data in the Quinapril Ischemic Event (QUIET) Trial
R S Lees, B Pitt, R C Chan, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
May 1, 1995
Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor
J W Nawrocki, S R Weiss, M H Davidson, et al.
Cardiovascular Drugs and Therapy
|
April 8, 2000
Angiotensin II formation in human vasculature after chronic ACE inhibition: a prospective, randomized, placebo-controlled study. QUO VADIS Investigators
M Oosterga, A A Voors, H Buikema, et al.
Circulation
|
August 1, 1996
Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study
G B Mancini, G C Henry, C Macaya, et al.
Page
of 1